BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma

European Journal of Haematology

Volumn 85, Issue 2, 2010, Pages 99-107

  Sterz, Jan ^a   Jakob, Christian ^a   Kuckelkorn, Ulrike ^a   Heider, Ulrike ^a   Mieth, Maren ^a   Kleeberg, Lorenz ^a   Kaiser, Martin ^a   Kloetzel, Peter M ^a   Sezer, Orhan ^a,b   Von Metzler, Ivana ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

apoptosis; cell cycle; multiple myeloma; NF B; proteasome

Indexed keywords

BSC 2118; CELL ENZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P21; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CANCER CELL CULTURE; CANCER INHIBITION; CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PHASE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW EXAMINATION; BUTANES; CELL CYCLE; CELL LINE, TUMOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKOCYTES, MONONUCLEAR; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANSLOCATION, GENETIC;

EID: 77954749665     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01450.x     Document Type: Article

References (44)

1. Jagannath S, Kyle RA, Palumbo A, Siegel DS, Cunningham S, Berenson J. The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma 2010 10 : E1 16.
2. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group (IMWG) Guidelines for the Management of Multiple Myeloma Patients Ineligible for Standard High-dose Chemotherapy with Autologous Stem Cell Transplantation. Leukemia 2009 23 : 1716 1730.
3. Sezer O. Myeloma bone disease: recent advances in biology, diagnosis and treatment. Oncologist 2009 14 : 276 283.
4. Königsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000 18 : 804 812.
5. Liebisch P, Döhner H. Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer 2006 42 : 1520 1529.
6. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000 95 : 4008 4010.
7. Gutiérrez NC, Castellanos MV, Martín ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007 21 : 143 150.
8. Bech-Otschir D, Helfrich A, Enenkel C, Consiglieri G, Seeger M, Holzhütter HG, Dahlmann B, Kloetzel PM. Polyubiquitin substrates allosterically activate their own degradation by the 26S proteasome. Nat Struct Mol Biol 2009 16 : 219 225.
9. Seemuller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W. Proteasome from Thermoplasma acidophilum: a threonine protease. Science 1995 268 : 579 582.
10. Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001 2 : 179 187.
11. Tanaka K, Kumatori A, Ii K, Ichihara A. Direct evidence for nuclear and cytoplasmic colocalization of proteasomes (multiprotease complexes) in liver. J Cell Physiol 1989 139 : 34 41.
12. Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999 97 : 431 434.
13. Naujokat C, Sarić T. Concise review: role and function of the ubiquitin-proteasome system in mammalian stem and progenitor cells. Stem Cells 2007 25 : 2408 2418.
14. Naujokat C, Fuchs D, Berges C. Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition. Biochim Biophys Acta 2007 1773 : 1389 1397.
15. von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007 21 : 2025 2034.
16. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 1996 227 : 564 569.
17. Pagano M. Cell cycle regulation by the ubiquitin pathway. FASEB J 1997 11 : 1067 1075.
18. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 1996 56 : 2649 2654.
19. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996 56 : 4620 4624.
20. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000 22 : 442 451.
21. Zavrski I, Naujokat C, Niemöller K, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker J, Possinger K, Sezer O. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003 129 : 383 391.
22. Ali R, Beksac M, Ozkalemkas F, Ozkocaman V, Ozkan A, Ozcelik T, Tunali A. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leuk Lymphoma 2007 48 : 1426 1428.
23. Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, Tachikawa T, Shin S, Ichihara A. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990 87 : 7071 7075.
24. Kanayama H, Tanaka K, Aki M, Kagawa S, Miyaji H, Satoh M, Okada F, Sato S, Shimbara N, Ichihara A. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 1991 51 : 6677 6685.
25. Bhui-Kaur A, Therwath A, Henry L, Chiesa J, Kurkure A, Scherrer K, Bureau JP. Increased proteasomal proteins in breast cancer cells and in neighboring normal cells in Parsi and non-Parsi populations. J Cancer Res Clin Oncol 1998 124 : 117 126.
26. Jakob C, Egerer K, Liebisch P, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007 109 : 2100 2105.
27. von Metzler I, Heider U, Mieth M, Lamottke B, Kaiser M, Jakob C, Sezer O. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. Exp Cell Res 2009 315 : 2471 2478.
28. Heider U, Kaiser M, Müller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006 77 : 233 238.
29. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007 110 : 1098 1104.
30. Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007 21 : 1875 1884.
31. Heider U, Kaiser M, Mieth M, Lamottke B, Rademacher J, Jakob C, Braendle E, Stover D, Sezer O. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009 82 : 31 8.
32. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003 348 : 2609 2617.
33. Braun HA, Umbreen S, Groll M, Kuckelkorn U, Mlynarczuk I, Wigand ME, Drung I, Kloetzel PM, Schmidt B. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J Biol Chem 2005 280 : 28394 28401.
34. Mlynarczuk-Bialy I, Roeckmann H, Kuckelkorn U, et al. Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. Cancer Res 2006 66 : 7598 7605.
35. Hecht M, von Metzler I, Sack K, Kaiser M, Sezer O. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp Cell Res 2008 314 : 1082 1093.
36. Campling BG, Pym J, Galbraith PR, Cole SP. Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells. Leuk Res 1988 12 : 823 831.
37. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994 84 : 1415 1420.
38. Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J, Jakob C, Sezer O. Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des 2007 13 : 471 485.
39. San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006 11 : 51 61. (Pubitemid 43152686)
40. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008 17 : 879 895.
41. Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 2006 4 : 2289 2300.
42. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004 6 : 203 208.
43. Heider U, Rademacher J, Lamottke B, Mieth M, Moebs M, von Metzler I, Assaf C, Sezer O. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol 2009 82 : 440 449.
44. Heider U, von Metzler I, Kaiser M, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008 80 : 133 142.